New antibody replacement therapy aims to shield vulnerable patients from serious infections
NCT ID NCT03238079
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a new intravenous immunoglobulin (IGIV) called PlasmaCap IG in adults and children aged 2 to 70 with primary immune deficiency diseases (PIDD). Participants receive regular infusions of the therapy for 12 months. The goal is to see if it prevents serious bacterial infections and maintains protective antibody levels, while also checking for safety and tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Human Immunoglobulin (10% IGIV)
What this could lead to
If successful, this could provide a new, safe option for replacing missing antibodies in people with primary immune deficiency, helping prevent serious infections.
What could go wrong
This is a mid-stage trial with only 63 participants, so results may not apply to everyone. As with any blood product, there is a risk of allergic reactions or transmission of infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE DEFICIENCY DISEASES (PIDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AAICPA
Irving, Texas, 75063, United States
-
AARA Research Center
Dallas, Texas, 75231, United States
-
Allergy Associates of the Palm Beaches, P.A.
West Palm Beach, Florida, 33408, United States
-
Allergy Partners of North Texas
Dallas, Texas, 75230, United States
-
CHU Ste-Justine
Montreal, Quebec, H3T 1C5, Canada
-
IMMUNOe Health & Research Centers
Centennial, Colorado, 80112, United States
-
Institute for Asthma and Allergy, PC
Chevy Chase, Maryland, 20815, United States
-
Optimed Research LTD
Columbus, Ohio, 43235, United States
-
Optimed Research Ltd.
Little Silver, New Jersey, 07739, United States
-
The Medical College of Wisconsin, Inc.
Milwaukee, Wisconsin, 53226, United States
-
University of California
Los Angeles, California, 92697, United States
-
University of South Florida
Tampa, Florida, 33620, United States